Hikma Pharmaceuticals, a leading FTSE 100 company in the pharmaceuticals sector, has seen a significant decline in its share price following the announcement of weaker financial forecasts and the scrapping
Hikma Pharmaceuticals, a leading FTSE 100 company in the pharmaceuticals sector, has seen a significant decline in its share price following the announcement of weaker financial forecasts and the scrapping
AstraZeneca, the United Kingdom’s most valuable publicly listed company, has secured the backing of leading shareholder advisory groups for its proposal to achieve a direct listing on the New York
The United Kingdom stands on the threshold of a radical transformation in obesity treatment, as Eli Lilly prepares to introduce a daily weight-loss pill, Orforglipron, in 2026, once regulatory approval






